Abstract 【Objective】 To investigate the effects of levocarnitine combined with alprostadil on renal function,oxidative stress and inflammation in patients with diabetic nephropathy (DN). 【Methods】 A total of 98 DN patients treated in Yulin Fifth Medical College from March 2019 to March 2021 were selected and divided into the observation group and the control group according to random number table method,with 49 cases in each group. The control group was treated with alprostadil,and the observation group was treated with L-carnitine on the basis of the control group,for consecutive 4 weeks. Clinical efficacy,renal function indexes [BUN,CYstatin C,24 h urinary protein,β2 microglobulin,24hUpro,β2-MG],oxidative stress indexes [MALondialdehyde (MDA),superoxide dismutase (SOD),reactive oxygen species (ROS)] and inflammatory factors [C-reactive protein (CRP), interleukin-1 β (IL-1β), interleukin-6 (IL-6), interleukin-17 (IL-17)] levels and the incidence of adverse reactions were compared between two groups. 【Results】 The total effective rate of observation group was 93.88%, which was significantly higher than that of control group (77.55%), and the difference was statistically significant (P<0.05). After treatment, the levels of BUN, CYS-C, 24hUpro, β2-MG, MDA, ROS, CRP, IL-1β and IL-6 in the observation group were significantly lower than those in the control group, while SOD was significantly higher than that in the observation group; The differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 Levocarnitine combined with alprostadil in the treatment of DN can improve the clinical curative effect, reduce the damage to the kidney, reducing oxidative stress and inflammation index.
JI Dong-lin,ZHANG Ya-qiong. Effects of Levocarnitine Combined with Alprostadil on Renal Function,Oxidative Stress and Inflammatory Response in Diabetic Nephropathy Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 644-647.
2022, Vol. 39 
